Amanda Murphy, Ph.D., focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.
In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.
Amanda’s technical experience includes anticancer agents, antibiotic susceptibility, antibodies, antiretrovirals, antipsychotics, bioethanol technology, biologics, blood clotting factors, cosmetics, diagnostic and detection systems, nucleic acid and protein technologies, Raman spectroscopy, recombinant organisms, small molecules, and vaccines.
Prior to joining Finnegan, Amanda received her Ph.D. from Cornell University, where she studied the molecular requirements for protein-lipid interactions during retroviral assembly and the lipid compositions of retroviral particles. She then gained significant experience as a technical specialist and a student associate at Finnegan during her studies in law school.
